Tianjin Chase Sun Pharmaceutical Co., Ltd.
-
Founded in:
2000-09-30 -
Country:
China -
Address:
West of Quanfa Road, Wuqing Development Zone, Tianjin New Technology Industrial Park -
Tax NO.:
9112000010409702XT -
Registered Funds:
3,004,154,837 yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| NORFLOXACIN LACTATE |
|
97867-34-0 | 1 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 1-p-anilino-2-pyrrolidone |
This product selectively acts on the central nervous system through the blood-brain barrier. Animal experiments have shown that this product has a good promoting effect on the memory reproduction process of normal rats' discrimination learning, and can fight against memory loss caused by hypoxia. It can effectively improve memory disorders caused by certain reasons.
More
This product selectively acts on the central nervous system through the blood-brain barrier. Animal experiments have shown that this product has a good promoting effect on the memory reproduction process of normal rats' discrimination learning, and can fight against memory loss caused by hypoxia. It can effectively improve memory disorders caused by certain reasons. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Piracetam |
This product is a brain metabolism improving drug, which is a cyclic derivative of r-aminobutyric acid. It has the effect of resisting brain function damage caused by physical and chemical factors. It can promote ATP in the brain, promote acetylcholine synthesis and positively enhance the conduction of nerve excitement, and has the effect of promoting brain metabolism. It can resist brain function damage caused by physical and chemical factors. It has an improving effect on retrograde hyperactivity caused by hypoxia. It can enhance memory and improve learning ability.
More
This product is a brain metabolism improving drug, which is a cyclic derivative of r-aminobutyric acid. It has the effect of resisting brain function damage caused by physical and chemical factors. It can promote ATP in the brain, promote acetylcholine synthesis and positively enhance the conduction of nerve excitement, and has the effect of promoting brain metabolism. It can resist brain function damage caused by physical and chemical factors. It has an improving effect on retrograde hyperactivity caused by hypoxia. It can enhance memory and improve learning ability. |
7491-74-9 | 25 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Nadroparin |
It has significant anti-coagulation factor Xa activity, and low anti-coagulation factor IIa or antithrombin activity (30 IU/ml). It can inhibit the formation of thrombi in vivo and in vitro and arteriovenous thrombi, but does not affect platelet aggregation and the binding of fibrinogen to platelets. When it exerts its antithrombotic effect, the possibility of bleeding is small. At the recommended dose for different indications, low molecular weight heparin does not prolong bleeding time. At the preventive dose, it does not significantly change APTT.
More
It has significant anti-coagulation factor Xa activity, and low anti-coagulation factor IIa or antithrombin activity (30 IU/ml). It can inhibit the formation of thrombi in vivo and in vitro and arteriovenous thrombi, but does not affect platelet aggregation and the binding of fibrinogen to platelets. When it exerts its antithrombotic effect, the possibility of bleeding is small. At the recommended dose for different indications, low molecular weight heparin does not prolong bleeding time. At the preventive dose, it does not significantly change APTT. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Nadroparin |
It has significant anti-coagulation factor Xa activity, and low anti-coagulation factor IIa or antithrombin activity (30 IU/ml). It can inhibit the formation of thrombi in vivo and in vitro and arteriovenous thrombi, but does not affect platelet aggregation and the binding of fibrinogen to platelets. When it exerts its antithrombotic effect, the possibility of bleeding is small. At the recommended dose for different indications, low molecular weight heparin does not prolong bleeding time. At the preventive dose, it does not significantly change APTT.
More
It has significant anti-coagulation factor Xa activity, and low anti-coagulation factor IIa or antithrombin activity (30 IU/ml). It can inhibit the formation of thrombi in vivo and in vitro and arteriovenous thrombi, but does not affect platelet aggregation and the binding of fibrinogen to platelets. When it exerts its antithrombotic effect, the possibility of bleeding is small. At the recommended dose for different indications, low molecular weight heparin does not prolong bleeding time. At the preventive dose, it does not significantly change APTT. |
0 |